Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cardiovascular & Hematological Agents in Medicinal Chemistry|January 24, 2018
Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver DiseaseVishal Patel, Amit Joharapurkar, Samadhan Kshirsagar, et al.
Canadian Journal of Physiology and Pharmacology|February 7, 2018
Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver diseaseVishal Patel, Amit Joharapurkar, Samadhan Kshirsagar, et al.
European Journal of Pharmacology|April 20, 2022
ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal modelsMukul R Jain, Rakesh B Patel, Kanaiyalal D Prajapati, et al.
Drug Research|February 4, 2017
Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent ModelHarilal Patel, Amit A Joharapurkar, Rajesh Bahekar, et al.
Bioorganic & Medicinal Chemistry Letters|April 13, 2019
Discovery of 1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-ones based novel, potent and PI3Kδ selective inhibitorsRajesh Bahekar, Bhushan Dave, Shubhangi Soman, et al.
Bioorganic & Medicinal Chemistry|January 11, 2011
Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonistsPankaj Makadia, Shailesh R Shah, Harikishore Pingali, et al.
Bioorganic Chemistry|November 20, 2022
Design, synthesis and biological evaluation of novel pyrazolo-pyrimidin-amines as potent and selective BTK inhibitorsDarshan Joshi, Rajesh Bahekar, Shubhangi Soman, et al.
Bioorganic Chemistry|April 26, 2020
Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitorsRajesh Bahekar, Nandini Panchal, Shubhangi Soman, et al.
Bioorganic & Medicinal Chemistry Letters|January 4, 2011
Modulation of PPAR subtype selectivity. Part 2: Transforming PPARα/γ dual agonist into α selective PPAR agonist through bioisosteric modificationPandurang Zaware, Shailesh R Shah, Harikishore Pingali, et al.
Pharmacology Research & Perspectives|August 14, 2020
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancerKrishnarup Ghoshdastidar, Hoshang Patel, Hitesh Bhayani, et al.
Pageof 4